Navigation Links
European Multiple Sclerosis Market in Dire Need of Increased Disease Awareness and Treatment Options, Cautions Frost & Sullivan
Date:3/14/2012

LONDON, March 14, 2012 /PRNewswire/ -- Limited awareness about the disease and its overall occurrence and progression among end-users is hampering the European multiple sclerosis (MS) market. This is being exacerbated by the limited availability of accurate diagnostic tools. There is, therefore, an immediate need for innovative and enhanced therapeutic and diagnostic tools that support improved diagnosis and expand the range of treatment options.

New analysis from Frost & Sullivan (http://www.pharma.frost.com), Analysis of the European Multiple Sclerosis Market, finds that the market earned revenues of approximately $3.2 billion in 2010 and estimates this to reach approximately $5.38 billion in 2017, growing at a compound annual growth rate (CAGR) of 7.2 per cent from 2010-2017. The segments covered include: immunosuppressants, immunomodulators and corticosteroids.

"The rising number of people suffering from MS is resulting in higher demand for therapeutics," notes Frost & Sullivan Research Analyst Deepika Pramod Chopda. "This, coupled with strong pipeline development, is pushing robust growth in the overall market."

MS is characterised as a chronic disease, commonly diagnosed in patients between 20-50 years of age. It affects more than 2.5 million people across the world, with Europe accounting for nearly 550,000 cases.

Significant research is currently underway to efficiently treat MS. Innovative treatment therapies, including biologics and oral drugs, are favouring market prospects.

"Refined drug delivery technologies, mode of drug delivery (oral or injectable), and several other factors will encourage the use of MS drugs among patients," adds Deepika. "Novel treatment options will also promote the concept of combination therapies, accelerating market development."

A key challenge at present is the inaccuracy in disease diagnosis due to the lack of sensitive diagnostic tools. Another issue is the absence of established treatment procedures.

"Non-compliance with MS treatment procedures remains a major challenge," explains Deepika. "Establishing end-user confidence has become difficult due to unsatisfactory therapeutic results."

Cumbersome and painful procedures discourage the progress of therapy. Simple advances, like the use of oral drugs instead of injections, will prove beneficial to promoting compliance with therapeutic regimes.

"Awareness raising through public healthcare forums and organisations about new developments and innovative treatment options will contribute toward establishing greater end-user confidence," concludes Deepika. "In the meantime, precautionary measures like adopting healthy lifestyle practices will help limit the incidence of the disease."

If you are interested in more information on this study, please send an e-mail with your contact details to Janique Morvan, Corporate Communications, at janique.morvan@frost.com.

Analysis of the European Multiple Sclerosis is part of the Pharmaceuticals & Biotechnology Growth Partnership Service programme, which also includes research in the following markets: European Biosimilars Market, Global Generics Market and European Autoimmune Diseases Therapeutics Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

Contact:
Janique Morvan
Corporate Communications – Europe
P: +33 (0)1 42 81 20 37
M: +33 (0)6 79 22 41 42
E: janique.morvan@frost.com

http://www.frost.com

 


'/>"/>
SOURCE Frost & Sullivan
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Intravenous Remodulin Approved for the Treatment of Pulmonary Arterial Hypertension in Most of the European Union
2. The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem
3. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
4. Inspiration Biopharmaceuticals Announces Acceptance of European Marketing Authorization Application for IB1001 for the Treatment of Hemophilia B
5. Elevation Pharmaceuticals Presents Positive Phase 2a Results in COPD Patients at the European Respiratory Society Annual Congress
6. Generex Makes Podium Presentation of Clinical Data on Generex Oral-lyn™ at European Association for the Study of Diabetes Annual Meeting
7. Metabolic Solutions Development Company Presents New Brown Fat Research at the European Association for the Study of Diabetes
8. European Medicines Agency Accepts Vanda Pharmaceuticals Inc.s Marketing Authorization Application For Oral Iloperidone Tablets
9. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
10. Kuros Announces Allowance of European Patent for Synthetic Biomaterials
11. BioSpecifics Technologies Corp. Announces Data Presentations at Upcoming XVI Annual Federation of the European Societies for Surgery of the Hand Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Cord Blood Corporation (NYSE: CO ) ("CCBC" ... collection, laboratory testing, hematopoietic stem cell processing and stem ... for the third quarter and first nine months of ... Third Quarter of Fiscal 2017 Highlights ... by 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)... 24, 2017  VWR Corporation (NASDAQ: VWR), the leading global ... production customers, today reported its financial results for the fourth ... Highlights: 4Q16 record quarterly net sales ... an organic basis. 4Q16 EMEA-APAC ... basis, while the Americas net sales increased 2.5%, or down ...
(Date:2/23/2017)... -- Financial Highlights ... unaudited)Three Months Ended December 31,Twelve Months Ended December 31,20162015% ... $           300$   ... Product Revenue 3539(10)%9498(4)%Kuvan Net Product ... 756025%297303(2)%Vimizim Net Product Revenue ...
(Date:2/23/2017)... JOSE, Calif. , Feb. 23, 2017 /PRNewswire/ ... exclusive license for two key immunotherapy technologies from ... first technology provides a method to monitor a ... such as PD-L1 and CTLA-4.  The second license ... if a patient is likely to have an ...
Breaking Biology Technology:
(Date:2/21/2017)... , February 21, 2017 ... 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr als ... einige Hindernisse zu überwinden gilt, um diese Prognose zu ... ... anderem die Mobilisierung der finanziellen Mittel für die Biobank, ...
(Date:2/10/2017)... , Feb 10, 2017 Research ... report "Personalized Medicine - Scientific and Commercial Aspects" ... ... medicine. Diagnosis is integrated with therapy for selection of treatment ... early detection and prevention of disease in modern medicine. Biochip/microarray ...
(Date:2/8/2017)... 2017 The biometrics market has reached ... of organizations, desires to better authenticate or identify ... and challenge questions), biometrics is quickly working its ... market is driven by use cases, though there ... enterprise uses cases, with consumer-facing use cases encompassing ...
Breaking Biology News(10 mins):